Table 3. Patients’ distribution and MTD cohorts.
| Cohort A | Cohort B | Cohort C | Total | |
|---|---|---|---|---|
| Number of patients (%) | ||||
| 28 (21%) | 22 (16%) | 85 (63%) | 135 | |
| Gender (male/female) | ||||
| 15/13* | 13/9* | 59/26* | 87/48 | |
| Age (median (range)) | ||||
| 60 (20–83) | 56 (27–77) | 57 (25–86) | 57 (20–86) | |
| Performance status | ||||
| ECOG 0 | 6* | 6* | 22* | 34 |
| ECOG 1 | 17* | 12* | 51* | 80 |
| ECOG 2 | 5* | 2* | 3* | 10 |
| RMH Prognostic score | ||||
| 0–1 | 10 (36%)† | 9 (41%)† | 35 (40%)† | 54 (40%) |
| 2–3 | 18 (64%)† | 13 (59%)† | 51 (60%)† | 81 (60%) |
| Non-progression rate | ||||
| 3-month NPR | 6 (21%)‡ | 11 (50%)‡ | 26 (31%)‡ | 43/135 (32%) |
| 6-month NPR | 3 (11%)‡ | 6 (27%)‡ | 12 (14%)‡ | 21/135 (16%) |
| Objective responses | ||||
| 1 | 3 | 1 | 5 |
ECOG=Eastern cooperative oncology group; MTD=maximal tolerated dose; RMH=Royal Marsden Hospital, NPR=non-progression rate.
*P=0.1.
†P=0.7.
‡P=0.9.